Evotec ex­pands glob­al dis­cov­ery, de­vel­op­ment ops with $300M Ap­tu­it buy­out

Ger­many’s Evotec is beef­ing up its con­tract drug de­vel­op­ment or­ga­ni­za­tion, buy­ing out ri­val Ap­tu­it in a deal that will add hun­dreds of sci­en­tists to its or­ga­ni­za­tion along with fa­cil­i­ties in Basel, Ox­ford and Verona, Italy. Evotec is pay­ing $300 mil­lion in cash for the com­pa­ny and its ros­ter of hun­dreds of bio­phar­ma clients that have looked to Ap­tu­it for every­thing from dis­cov­ery through clin­i­cal ser­vices and in­to man­u­fac­tur­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER